Sendero Wealth Management LLC Has $3.77 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Sendero Wealth Management LLC lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 16.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 54,272 shares of the company's stock after acquiring an additional 7,859 shares during the period. Sendero Wealth Management LLC's holdings in Novo Nordisk A/S were worth $3,769,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Revolve Wealth Partners LLC increased its stake in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares during the last quarter. Golden State Equity Partners grew its stake in Novo Nordisk A/S by 327.4% in the fourth quarter. Golden State Equity Partners now owns 3,146 shares of the company's stock valued at $271,000 after purchasing an additional 2,410 shares in the last quarter. Stock Yards Bank & Trust Co. raised its stake in shares of Novo Nordisk A/S by 16.5% during the 4th quarter. Stock Yards Bank & Trust Co. now owns 4,604 shares of the company's stock worth $396,000 after purchasing an additional 651 shares in the last quarter. Princeton Global Asset Management LLC lifted its holdings in shares of Novo Nordisk A/S by 56.1% during the 4th quarter. Princeton Global Asset Management LLC now owns 2,781 shares of the company's stock valued at $239,000 after buying an additional 1,000 shares during the last quarter. Finally, Catalina Capital Group LLC raised its holdings in Novo Nordisk A/S by 17.5% during the fourth quarter. Catalina Capital Group LLC now owns 4,264 shares of the company's stock valued at $367,000 after buying an additional 634 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded up $0.53 on Thursday, hitting $72.57. The company's stock had a trading volume of 5,088,580 shares, compared to its average volume of 6,858,486. The company has a fifty day moving average price of $65.67 and a 200-day moving average price of $81.09. The firm has a market cap of $325.64 billion, a P/E ratio of 22.06, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. BMO Capital Markets restated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $128.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.